Rutgers University Research Center and Janssen Develop Continuous Manufacturing Process

Article

Rutgers engineers constructed a direct compaction line in collaboration with Janssen.

Researchers in the Engineering Research Center for Structured Organic Particulate Systems (C-SOPS) at Rutgers, the State University of New Jersey, have collaborated with Janssen to develop a direct-compaction line using continuous manufacturing principles. C-SOPS researchers built a full-scale production line at the Rutgers to test concepts and define a design space. Janssen is now constructing a line based on that design, which is targeted for completion in 2014.

C-SOPS, based on the Rutgers University campus and in partnership with Purdue University, The New Jersey Institue of Technology, and The University of Puerto Rico at Mayagüez, brings together a cross-disciplinary group of engineers, scientists, and industry leaders from academia, pharmaceutical manufacturers, and equipment manufacturers. C-SOPS has been investigating continuous manufacturing concepts since 2006 and has worked on both the fundamental science and commercialization of advanced pharmaceutical manufacturing. The continuous direct compaction line replaces the traditional multi-stage batch process by integrating feeders, mills, blenders, and a tablet press into a single continuous process.

In developing the line, C-SOPS researchers defined parameters and performed design space experiments to evaluate the effect of parameter changes. “Because the process is continuous, we were able to measure parameter-change effects in nearly real time; we performed a full set of design experiments with dozens of conditions, in hours rather than days to weeks, and used a fraction of the API needed for batch processing,” explains Douglas Hausner, associate director for industrial relations and business development at C-SOPS.

Recent Videos
Preeya Beczek, managing director and co-founder of Beczek.COM, chats about industry trends from 2024 and which of those might impact the industry in 2025, including the big trend of AI.
Kate Coleman, vice president regulatory affairs, quality and compliance, Arriello, chats about industry trends and technological advances.
William K. Oh, MD
Adam Sherlock, CEO of Qinecsa, discusses the changing political landscapes in the US and Europe and how that may affect the bio/pharma industry.
Adam Sherlock, CEO of Qinecsa Solutions
Buy, Sell, Hold: Cell and Gene Therapy
Related Content
© 2025 MJH Life Sciences

All rights reserved.